TY - JOUR
T1 - Determinants of VIA (visual inspection of the cervix after acetic acid application) positivity in cervical cancer screening of women in a peri-urban area in Andhra Pradesh, India
AU - Vedantham, Haripriya
AU - Silver, Michelle I.
AU - Kalpana, B.
AU - Rekha, C.
AU - Karuna, B. P.
AU - Vidyadhari, K.
AU - Mrudula, S.
AU - Ronnett, Brigitte M.
AU - Vijayaraghavan, K.
AU - Ramakrishna, Gayatri
AU - Sowjanya, Pavani
AU - Laxmi, Shantha
AU - Shah, Keerti V.
AU - Gravitt, Patti E.
PY - 2010/5
Y1 - 2010/5
N2 - Objectives: Visual inspection of the cervix after acetic acid application (VIA) is widely recommended as the method of choice in cervical cancer screening programs in resource-limited settings because of its simplicity and ability to link with immediate treatment. In testing the effectiveness of VIA, human papillomavirus DNA testing, and Pap cytology in a population-based study in a peri-urban area in Andhra Pradesh, India, we found the sensitivity of VIA for detection of cervical intraepithelial neoplasia grade 2 and worse (CIN2+) to be 26.3%, much lower than the 60% to 90% reported in the literature. We therefore investigated the determinants of VIA positivity in our study population. Methods: We evaluated VIA positivity by demographics and reproductive history, results of clinical examination, and results from the other screening methods. Results: Of the 19 women diagnosed with CIN2+, only 5 were positive by VIA (positive predictive value, 3.1%). In multivariate analysis, VIA positivity (12.74%) was associated with older age, positive Pap smear, visually apparent cervical inflammation, and interobserver variation. Cervical inflammation of unknown cause was present in 21.62% of women. In disease-negative women, cervical inflammation was associated with an increase in VIA positivity from 6.1% to 15.5% (P < 0.001). Among the six gynecologists who performed VIA, the positivity rate varied from 4% to 31%. Conclusions: The interpretation of VIA is subjective and its performance cannot be readily evaluated against objective standards. Impact: VIA is not a robust screening test and we caution against its use as the primary screening test in resource-limited regions.
AB - Objectives: Visual inspection of the cervix after acetic acid application (VIA) is widely recommended as the method of choice in cervical cancer screening programs in resource-limited settings because of its simplicity and ability to link with immediate treatment. In testing the effectiveness of VIA, human papillomavirus DNA testing, and Pap cytology in a population-based study in a peri-urban area in Andhra Pradesh, India, we found the sensitivity of VIA for detection of cervical intraepithelial neoplasia grade 2 and worse (CIN2+) to be 26.3%, much lower than the 60% to 90% reported in the literature. We therefore investigated the determinants of VIA positivity in our study population. Methods: We evaluated VIA positivity by demographics and reproductive history, results of clinical examination, and results from the other screening methods. Results: Of the 19 women diagnosed with CIN2+, only 5 were positive by VIA (positive predictive value, 3.1%). In multivariate analysis, VIA positivity (12.74%) was associated with older age, positive Pap smear, visually apparent cervical inflammation, and interobserver variation. Cervical inflammation of unknown cause was present in 21.62% of women. In disease-negative women, cervical inflammation was associated with an increase in VIA positivity from 6.1% to 15.5% (P < 0.001). Among the six gynecologists who performed VIA, the positivity rate varied from 4% to 31%. Conclusions: The interpretation of VIA is subjective and its performance cannot be readily evaluated against objective standards. Impact: VIA is not a robust screening test and we caution against its use as the primary screening test in resource-limited regions.
UR - http://www.scopus.com/inward/record.url?scp=77952077825&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-09-1282
DO - 10.1158/1055-9965.EPI-09-1282
M3 - Article
C2 - 20447927
AN - SCOPUS:77952077825
SN - 1055-9965
VL - 19
SP - 1373
EP - 1380
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 5
ER -